Genetic testing to find BRCA 1/2 mutation for detecting breast and ovarian cancer


NGenebio
Reagents
Detecting breast and ovarian cancer
BRCAaccuTest™ PLUS with CE-IVD certificate for HBOC Breast/Ovarian Cancer Test
Genetic testing to find BRCA 1/2 mutation for detecting breast and ovarian cancer
| BRCAaccuTest™ PLUS | ||
|---|---|---|
| Certification | CE-IVD | |
| Target Gene | Breast Cancer/Ovarian cancer HBOC (Hereditary breast and ovarian cancer syndrome) |
|
| Treatment-enhancing methods | Method of Amplicon | |
| Numbers | 12 (6+6) tests (1 tests for DNA control) |
24 tests (1 tests for DNA control) |
| Samples | Blood, FFPE, biopsy tissue | |
| Amount of DNA input | 10-30 ng | |
| Target Gene | BRCA1 / BRCA2 | |
| Target Area | 22.4 kb (all protein coding zones, joins, startup zones selected, UTR, intron regions) | |
| amplicon | 160 (2 pools) | |
| Timing | >5 hrs | |
| Variant | SNV, In, Del, Dup, CNV* | |
| NGS platform & reagent | illumina MiSeq, MiSeq Dx / MiSeq Reagent Nano, Micro kit, v2, 300cycles | |
| Throughput Sample | Germline (11) / Somatic (5) | Germline (23) |
| Analysis Solution | NGeneAnalySys™ (CE) | |
*CNV: Only ROU
Supplier
Ngenebio


The EntroGen NGS Targeted Hotspot Panel is a comprehensive assay that detects clinically relevant mutations in solid tumors using next-generation sequencing, compatible with fresh frozen and FFPE samples. It offers high sensitivity, low DNA input, and the ability to batch up to 12 samples in a single run, making it ideal for labs with limited sample volumes.



SOLIDaccuTest™ is an excellent tool for discovering variants associated with solid tumors using a comprehensive approach to next-generation sequencing (NGS). It reflects the latest research trends and is optimized for medical purposes by selecting essential genes of solid tumors including lung, colon, breast, skin brain, stomach and ovarian cancers, etc.



SOLIDaccuTest™ is an excellent tool to explorer variants associated with solid tumors using a comprehensive method of next-generation sequencing (NGS). It reflects the latest research trends and is optimized for the medical purpose by selecting essential genes of solid tumors including lung, colon, breast, skin brain, gastric, ovarian cancers, etc.


The NextSeq 2000 Sequencing System uses patterned flow cells similar to those that power the NovaSeq™ 6000 System. The result is a highly flexible and scalable benchtop system that offers the highest cluster density flow cell of any on-market NGS system to date, driving down the cost per gigabase (Gb) of the sequencing run.


The PANA RealTyper™ HPV Screening Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC


PANA RealTyperTM HPV Kit is a CE marked diagnostic device in accordance with the European Union in vitro Diagnostic Medical Device Directive 98/79/EC.


DxFLEX is a new clinical flow cytometry platform derived from the successful CytoFLEX. The advanced sensitivity and intuitive software DxFLEX makes flow cytometry routine for both novice and expert flow cytometry technicians and promotes standardization. Functionality in the autoloader facilitates accurate results and sample tracking.


Model: iSeq 100
Manufacturer: Illumina/USA
Illumina’s smallest next-generation DNA sequencing system, with small, fast and efficient sequencing throughput, suitable for all labs
– Fast data generation: Suitable for small projects, on a dedicated device, low throughput with fast turnaround times
– Convenient operation: Control the sequencing process from start to finish and ensure independent sequencing instead of outsourcing.


TruSight Tumor 26 Kit includes library preparation reagent set and uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 26 genes that are commonly related to mutations in solid tumors and somatic variants


Model: MiSeq
Manufacturer: Illumina/USA
– The MiSeq System combines cluster generation, amplification, sequencing and data analysis on a single system
– The system is most widely used, with next-generation sequencing technology – Sequencing by Synthesis – SBS